Fieldview Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Fieldview Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$567K	Buy	+6,392	New	+$466K	0.16%	206

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fieldview Capital Management's SYRE Position: Q2 2026 in Review

Fieldview Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 6,392 shares worth $567K. The stake represents 0.16% of the portfolio and ranks #206 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Fieldview Capital Management held 6,392 shares of Spyre Therapeutics worth $567K as of Q2 2026.
Spyre Therapeutics was a new Fieldview Capital Management position in Q2 2026.
Spyre Therapeutics made up 0.16% of Fieldview Capital Management's portfolio in Q2 2026, its #206 holding.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.